Researchers at TGen have devised a faster and less expensive way to identify genetic variants in the human genome. By using bar-coded multiplexed sequencing, scientists can index portions of the nearly 3-billion-base genetic code, making it easier to zero in on regions most likely to show variations in genetic traits.
Researchers identified variations in the MYH9 gene strongly associated with FSGS and HIV-associated FSGS among African-Americans, with a risk 300-500% higher than whites. The findings shed light on common genetic pathways to prevent kidney disease progression.
Researchers identified eEF2K as a key player in enabling the rapid production of Arc protein, crucial for long-term memory formation. The paradoxical mechanism involves eEF2K inhibiting protein translation while also facilitating Arc protein synthesis.
Researchers found that adding four cycles of Taxotere to a sequential regimen of epirubicin and cyclophosphamide, methotrexate and fluorouracil reduces recurrence and death rates in patients with node-positive early stage breast cancer. This advantage comes at an increased toxicity level.
Scientists at Dana-Farber Cancer Institute have identified a previously unsuspected gene, CDK8, as a cancer-causing gene in many colon cancers. The study suggests that blocking CDK8 may be useful against tumors driven by overactive beta-catenin.
University of Utah engineers have developed a new way to slice thin wafers of germanium for use in high-efficiency solar cells. The new method, wire electrical discharge machining (WEDM), reduces waste and breakage of the brittle semiconductor, making it more economical to produce such cells.
The University of Queensland's new center, the Pacific Malaria Initiative Support Centre (PacMISC), is part of a global effort to eliminate malaria in low and middle-income countries. PacMISC will focus on Vanuatu and Solomon Islands, providing flexible assistance to national malaria control programs.
A phase II trial involving 45 patients found that an alternating regimen of chemotherapy and radiotherapy, plus cetuximab, yields favorable complete response rates and long-term results comparable to the best reported in literature. However, skin toxicity and toxicities resulting in patient deaths were also observed.
The SITS-ISTR study found that alteplase was safe and effective when given 3-4.5 hours after stroke onset, similar to the traditional 3-hour treatment window. Outcome measures were comparable in both groups, with similar mortality rates, brain haemorrhage risk, and independence at 3 months.
Researchers have identified a new gene variant linked to non-diabetic end-stage renal disease in African Americans, increasing their risk of kidney failure. The MYH9 gene variant is found more frequently among individuals with West African ancestry and may interact with environmental factors to cause the disease.
Researchers found that patients with specific EGFR gene mutations can live almost two years on average when treated with erlotinib, outperforming chemotherapy by two-to-three fold. The study identified a subgroup of 15-22% patients who can benefit from targeted therapies